Etonogestrel
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Etonogestrel: Amenorrhea (disease)
One-Sentence Summary
Etonogestrel is a progestin hormone marketed in Canada in a contraceptive implant and vaginal rings. The TxGNN model predicts it may be relevant to amenorrhea, but there are 0 clinical trials and 1 publication (unrelated to this drug or indication) behind this prediction. The prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 0.9984 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on general pharmacology, etonogestrel is a progestin that suppresses ovulation and thins the endometrium.
Amenorrhea is a well-known effect of the implant, usually seen as a bleeding-pattern outcome of use. So a biological link exists. However, this is an expected pharmacologic effect, not a therapeutic goal that has been tested. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other predicted indications are all L5 and none has any trials or relevant literature:
- Breast fibrocystic disease (0.9961)
- Blunt duct adenosis of breast (0.9929)
- Apocrine adenosis of breast (0.9929)
- Benign mammary dysplasia (0.9921)
These are benign breast conditions where progestins might oppose estrogen-driven proliferation. This rationale is theoretical only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33430924 | 2021 | RCT protocol | Trials | Study protocol for BIO101 in preventing respiratory deterioration in COVID-19 pneumonia. Unrelated to etonogestrel or amenorrhea, so it gives no supporting evidence. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02499509 | NEXPLANON | Not listed | Not listed |
| 02253186 | NUVARING | Not listed | Not listed |
| 02520028 | HALOETTE | Not listed | Not listed |
Safety Considerations
Knowledge-graph contraindication signals (from drug-disease links in the TxGNN knowledge graph, not from label text) include:
- Cardiovascular and metabolic: hypertension, coronary artery disease, thrombophlebitis, diabetes mellitus, diabetic ketoacidosis, hyperlipidemia, hypertriglyceridemia, obesity
- Liver, gallbladder and kidney disease
- Neurological: epilepsy, migraine
- Female breast carcinoma
- Others: porphyria, systemic lupus erythematosus, asthma, anxiety and related disorders
Drug interactions: 100 interactions were found. The 20 shown in the data are all rated Moderate. They fall mainly into these groups:
- Antidiabetic agents: acarbose, metformin, glimepiride, chlorpropamide, alogliptin, saxagliptin, canagliflozin, dapagliflozin, empagliflozin, albiglutide, dulaglutide, semaglutide, and insulins (aspart, degludec, detemir, glargine, glulisine)
- Others: aprepitant, clarithromycin, linaclotide
Please refer to the package insert for official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is model prediction only (L5). No trials exist, and the one linked publication is unrelated. Amenorrhea is an expected effect of etonogestrel rather than a treatment target, so it is hard to frame as a repurposing opportunity.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data
- Approved indication text for each Canadian license
- Relevant clinical or observational studies of etonogestrel in amenorrhea or benign breast conditions
- A clear clinical rationale for whether amenorrhea would be a therapeutic goal rather than a side effect
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.